Table 2 Outcomes

Best response

 CR

9 (45%)

6 (30%)

12 (21.4%)

0

 CRi

3 (15%)

5 (25%)

7 (12.5%)

1 (12.5%)

 MLFS

4 (20%)

3 (15%)

8 (14.3%)

0

 PR

0

0

1 (1.8%)

0

No response

4 (20%)

6 (30%)

28 (50%)

7 (87.5%)

CR/CRi

12 (60%)

11 (55%)

19 (33.9%)

1 (12.5%)

ORR (CR/CRi/MLFS)

16 (80%)

14 (70%)

27 (48.2%)

1 (12.5%)

Complete cytogenetic remission

8 (40%)

10 (50%)

6 (10.7%)

0

Best molecular response^

 MMR

2/17 (11.7%)

1/16 (6.3%)

1/47 (2.1%)

0

 MR⁴

2/17 (11.7%)

2/16 (12.5%)

0

0

 MR^4.5

1/17 (5.9%)

0

1/47 (2.1%)

0

Time to best response (months)

0.9

[0.7–6.9]

2.2

[0.8–5.5]

2.1

[0.6–16.3]

0.6

[0.6–0.6]

Proceeded to ASCT on this regimen

7 (35%)

6 (30%)

6* (10.7%)

1 (12.5%)

Median time to ASCT (months)

3.4 [1.5–7.9]

5.7 [2.9–8]

3.5 [2.5–5.7]

1.3 [1.3–1.3]

Median EFS (months)

5.2

[0.8–160.7]

5.0

[1.2–96.1]

4.8

[0.5–129.6]

2.2

[0.8–4.1]

Median RFS (months)

5.5

[0.5–159.8]

4.7

[0.6–93.5]

4.6

[0.2–127.7]

3.5

[3.5–3.5]

Median OS (months)

12.9

[0.8–160.7]

10.1

[1.2–96.1]

10.7

[0.5–244.3]

3.4

[0.8–48.9]

Relapse after initial objective response

6/16

6/14

17/27

0/1

EM relapse**

3/6 (50%)

1/6 (16.7%)

3/17 (17.6%)

0/1 (0%)

Early mortality

 30-day mortality

1 (5%)

0

1 (1.8%)

1 (12.5%)

 60-day mortality

3 (15%)

2 (10%)

1 (1.8%)

3 (37.5%)

5-year rates

 CIR

51%

54%

80%

100%

 EFS

27%

19%

5%

0%

 OS

30%

28%

13%

0%